Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised double blind placebo controlled clinical trial of rituximab in primary Sjögren's syndrome
2010-021430-64Phase 3Completed
- Sponsor
- University of Leeds
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary Sjögren's syndrome comparing Rituximab (MabThera) with Placebo (2 arms). Primary endpoint: Primary clinical response at 48 weeks. Started Nov 2010; status: completed.
02
Drugs
rituximab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2010-021430-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021430-64.